Non-Hodgkin's lymphoma: in a class all its own - PubMed (original) (raw)
Affiliations
- PMID: 11877913
Non-Hodgkin's lymphoma: in a class all its own
C P Titcomb Jr. J Insur Med. 2001.
Abstract
Non-Hodgkin's lymphoma (NHL) incidence rates have increased more than 50% over the past 15 years, making it the sixth leading cause of death from cancer in the United States and the fourth most significant malignancy in terms of economic impact. Comparable trends are noted worldwide. Improved diagnostic techniques have resulted in reclassifying some tumors that in the past would have been classified as Hodgkin's disease. In this article, the latest diagnostic, prognostic, and treatment options for NHL are reviewed and a cross-reference chart for these evolving class systems provided.
Similar articles
- Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.
Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Müller AM, et al. Ann Hematol. 2005 Jan;84(1):1-12. doi: 10.1007/s00277-004-0939-7. Epub 2004 Oct 9. Ann Hematol. 2005. PMID: 15480663 Review. - Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence.
Hartge P, Devesa SS. Hartge P, et al. Cancer Res. 1992 Oct 1;52(19 Suppl):5566s-5569s. Cancer Res. 1992. PMID: 1394175 Review. - Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A. Salzburg J, et al. J Clin Oncol. 2007 Sep 1;25(25):3915-22. doi: 10.1200/JCO.2007.11.0700. J Clin Oncol. 2007. PMID: 17761975 - The epidemiology of non-Hodgkin's lymphoma.
Fisher SG, Fisher RI. Fisher SG, et al. Oncogene. 2004 Aug 23;23(38):6524-34. doi: 10.1038/sj.onc.1207843. Oncogene. 2004. PMID: 15322522 Review. - Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004).
Abdel-Fattah MM, Yassine OG. Abdel-Fattah MM, et al. Eur J Cancer Prev. 2007 Oct;16(5):479-85. doi: 10.1097/01.cej.0000243858.91642.c9. Eur J Cancer Prev. 2007. PMID: 17923821
Cited by
- Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression.
Vogel CF, Li W, Sciullo E, Newman J, Hammock B, Reader JR, Tuscano J, Matsumura F. Vogel CF, et al. Am J Pathol. 2007 Nov;171(5):1538-48. doi: 10.2353/ajpath.2007.070406. Epub 2007 Sep 6. Am J Pathol. 2007. PMID: 17823287 Free PMC article. - Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).
Burgess SC, Young JR, Baaten BJ, Hunt L, Ross LN, Parcells MS, Kumar PM, Tregaskes CA, Lee LF, Davison TF. Burgess SC, et al. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13879-84. doi: 10.1073/pnas.0305789101. Epub 2004 Sep 8. Proc Natl Acad Sci U S A. 2004. PMID: 15356338 Free PMC article.
MeSH terms
LinkOut - more resources
Miscellaneous